RYZUMVI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ryzumvi, and when can generic versions of Ryzumvi launch?
Ryzumvi is a drug marketed by Famygen Life Sci and is included in one NDA. There are six patents protecting this drug.
This drug has twenty-three patent family members in sixteen countries.
The generic ingredient in RYZUMVI is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ryzumvi
A generic version of RYZUMVI was approved as phentolamine mesylate by HIKMA on March 11th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RYZUMVI?
- What are the global sales for RYZUMVI?
- What is Average Wholesale Price for RYZUMVI?
Summary for RYZUMVI
International Patents: | 23 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
What excipients (inactive ingredients) are in RYZUMVI? | RYZUMVI excipients list |
DailyMed Link: | RYZUMVI at DailyMed |
Pharmacology for RYZUMVI
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |
US Patents and Regulatory Information for RYZUMVI
RYZUMVI is protected by six US patents and one FDA Regulatory Exclusivity.
Patents protecting RYZUMVI
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PHARMACOLOGICALLY-INDUCED MYDRIASIS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting RYZUMVI
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RYZUMVI
See the table below for patents covering RYZUMVI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2020087021 | ⤷ Sign Up | |
Canada | 3116589 | ⤷ Sign Up | |
Japan | 6335927 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |